ThermoGenesis Launches Comprehensive Suite of COVID-19 Products and Services to Better Detect, Track and Fight Novel Coronavirus
By LabMedica International staff writers Posted on 03 Sep 2020 |
Illustration
ThermoGenesis Holdings, Inc. (Rancho Cordova, CA, USA), along with its joint venture ImmuneCyte Life Sciences, Inc.’s (Irvine, CA, USA), has launched a comprehensive COVID-19 product line that will combine diagnostic, therapeutic and service offerings to better detect, track and fight the novel coronavirus.
The spread of COVID-19 has led to a significant unmet need for rapid disease diagnosis, systematic serological surveillance and improved therapeutics, to precede and complement the introduction of vaccines. In response, ThermoGenesis, along with its joint venture ImmuneCyte, is developing a comprehensive list of RT-PCR and antigen test products to complement its SARS-CoV-2 IgM/IgG Antibody Test Kit, which has already been granted Emergency Use Authorization (EUA). The joint venture also plans to offer full CLIA certified lab testing services to its clients, making ThermoGenesis a one-stop shop for all testing needs. Additionally, the ImmuneCyte joint venture is actively developing a robust therapeutic pipeline to treat COVID-19.
"The comprehensive diagnostic and therapeutic product pipeline we envisage for COVID-19 will facilitate ThermoGenesis' ability to become a one-stop solution for our customers," said Chris Xu, Ph.D, Chairman and Chief Executive Officer of ThermoGenesis. "This multi-pronged approach, we believe, will be critical to reopening the economy, tracking the virus, and minimizing the loss of life as we continue to develop and expand our product solutions for COVID-19."
Related Links:
ThermoGenesis Holdings, Inc.
ImmuneCyte Life Sciences, Inc.
The spread of COVID-19 has led to a significant unmet need for rapid disease diagnosis, systematic serological surveillance and improved therapeutics, to precede and complement the introduction of vaccines. In response, ThermoGenesis, along with its joint venture ImmuneCyte, is developing a comprehensive list of RT-PCR and antigen test products to complement its SARS-CoV-2 IgM/IgG Antibody Test Kit, which has already been granted Emergency Use Authorization (EUA). The joint venture also plans to offer full CLIA certified lab testing services to its clients, making ThermoGenesis a one-stop shop for all testing needs. Additionally, the ImmuneCyte joint venture is actively developing a robust therapeutic pipeline to treat COVID-19.
"The comprehensive diagnostic and therapeutic product pipeline we envisage for COVID-19 will facilitate ThermoGenesis' ability to become a one-stop solution for our customers," said Chris Xu, Ph.D, Chairman and Chief Executive Officer of ThermoGenesis. "This multi-pronged approach, we believe, will be critical to reopening the economy, tracking the virus, and minimizing the loss of life as we continue to develop and expand our product solutions for COVID-19."
Related Links:
ThermoGenesis Holdings, Inc.
ImmuneCyte Life Sciences, Inc.
Latest COVID-19 News
- New Immunosensor Paves Way to Rapid POC Testing for COVID-19 and Emerging Infectious Diseases
- Long COVID Etiologies Found in Acute Infection Blood Samples
- Novel Device Detects COVID-19 Antibodies in Five Minutes
- CRISPR-Powered COVID-19 Test Detects SARS-CoV-2 in 30 Minutes Using Gene Scissors
- Gut Microbiome Dysbiosis Linked to COVID-19
- Novel SARS CoV-2 Rapid Antigen Test Validated for Diagnostic Accuracy
- New COVID + Flu + R.S.V. Test to Help Prepare for `Tripledemic`
- AI Takes Guesswork Out Of Lateral Flow Testing
- Fastest Ever SARS-CoV-2 Antigen Test Designed for Non-Invasive COVID-19 Testing in Any Setting
- Rapid Antigen Tests Detect Omicron, Delta SARS-CoV-2 Variants
- Health Care Professionals Showed Increased Interest in POC Technologies During Pandemic, Finds Study
- Set Up Reserve Lab Capacity Now for Faster Response to Next Pandemic, Say Researchers
- Blood Test Performed During Initial Infection Predicts Long COVID Risk
- Low-Cost COVID-19 Testing Platform Combines Sensitivity of PCR and Speed of Antigen Tests
- Finger-Prick Blood Test Identifies Immunity to COVID-19
- Quick Test Kit Determines Immunity Against COVID-19 and Its Variants